|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | H pylori infection and other risk factors associated with peptic ulcers in Turkish patients: A retrospective study显示文摘AIM: To identify and evaluate the relative impact of H pylori infection and other risk factors on the occurrence of gastric ulcer (GU), duodenal ulcer (DU) and gastritis in Turkish patients. METHODS: A total of 4471 patients (48.3% female) out of 4863 attended the Samatya hospital in Istanbul (June 1999 - October 2003) were included. The records of H pylori status (CLO-test), endoscopic f indings of GU, DU and gastritis, personal habits (smoking, alcohol intake) and medication [non-steroidal anti-inflammatory drugs (NSAIDs), aspirin intake] were analyzed using multi-way frequency analysis. RESULTS: We have found that GU in the presence of H pylori had significant association with aspirin (P = 0.0001), alcohol (P = 0.0090) and NSAIDs (P = 0.0372). DU on the other hand had significant association with aspirin/ smoking/NSAIDs (P = 0.0259), aspirin/alcohol (P = 0.0002) and aspirin/smoking (P = 0.0233), also in the presence of H pylori. In the absence of H pylori GU had significant association with alcohol/NSAIDs (P = 0.0431), and NSAIDs (P = 0.0436). While DU in the absence of H pylori had significant association with smoking/alcohol/ NSAIDs (P = 0.0013), aspirin/NSAIDs (P = 0.0334), aspirin/alcohol (P = 0.0360). CONCLUSION: In the presence of H pylori, aspirin, alcohol and NSAIDs intake act as an independent risk factors that had an augmenting impact on the occurrence of GU and only together on the occurrence of DU in Turkish patients. | Barik A Salih M Fatih Abasiyanik Nizamettin Bayyurt Ersan Sander | 2007 | World Journal of Gastroenterology2007，13，23： | 11 |
| 2 | Constipation-predominant irritable bowel syndrome: A review of current and emerging drug therapies显示文摘Irritable bowel syndrome(IBS) is a highly prevalent medical condition that adversely affects patient quality of life and constitutes a significant economic burden on healthcare resources. A large proportion of patients suffer from the constipation subtype of IBS(IBS-C), most commonly afflicting older individuals and those with a lower socioeconomic status. Conventional pharmacologic and nonpharmacologic treatment options have limited efficacies and/or significant adverse events, which lead to increased long-term health care expenditures. Failure to effectively treat IBS-C patients over the past decades has largely been due to a poor understanding of disease pathophysiology, lack of a global view of the patient, and an inappropriate selection of patients and treatment endpoints in clinical trials. In recent years, however, more effective and safer drugs have been developed for the treatment of IBS-C. The advancement in the area of pharmacologic treatment is based on new knowledge of the pathophysiologic basis of IBS-C and the development of drugs with increased selectivity within pharmacologic classes with recognized efficacies. This narrative review covers the spectrum of available drugs and their mechanisms of action, as well as the efficacy and safety profiles of each as determined in relevant clinical trials that have investigated treatment options for IBS-C and chronic constipation. A brief summary of laxative-based treatment options is presented, followed by up-to-date assessments for three classes of drugs: prokinetics, prosecretory agents, and bile acid modulators. | Khaled A Jadallah Susan M Kullab David S Sanders | 2014 | World Journal of Gastroenterology2014，20，27： | 9 |
| 3 | Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density显示文摘 | W.S Simonet D.L Lacey C.R Dunstan M Kelley M.-S Chang R Lüthy H.Q Nguyen S Wooden L Bennett T Boone G Shimamoto M DeRose R Elliott A Colombero H.-L Tan G Trail J Sullivan E Davy N Bucay L Renshaw-Gegg T.M Hughes D Hill W Pattison P Campbell S Sander G Van | 1997 | Cell1997，，2： | 6 |
| 4 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial显示文摘 | Geert D’Haens Filip Baert Gert van Assche Philip Caenepeel Philippe Vergauwe Hans Tuynman Martine De Vos Sander van Deventer Larry Stitt Allan Donner Severine Vermeire Frank J Van De Mierop Jean-Charles R Coche Janneke van der Woude Thomas Ochsenkühn Ad A | 2008 | The Lancet2008，，9613： | 5 |
| 5 | Endoscopic retrograde cholangiopancreatography:Current practice and future research显示文摘Endoscopic retrograde cholangiopancreatography(ERCP)has evolved from a primarily diagnostic to therapeutic procedure in hepatobiliary and pancreatic disease.Most commonly,ERCPs are performed for choledocholithiasis with or without cholangitis,but improvements in technology and technique have allowed for management of pancreatic duct stones,benign and malignant strictures,and bile and pancreatic leaks.As an example of necessity driving innovation,the new disposable duodenoscopes have been introduced into practice.With the advantage of eliminating transmissible infections,they represent a paradigm shift in quality improvement within ERCP.With procedures becoming more complicated,the necessity for anesthesia involvement and safety of propofol use and general anesthesia has become better defined.The improvements in endoscopic ultrasound(EUS)have allowed for direct bile duct access and EUS facilitated bile duct access for ERCP.In patients with surgically altered anatomy,selective cannulation can be performed with overtube-assisted enteroscopy,laparoscopic surgery assistance,or the EUS-directed transgastric ERCP.Cholangioscopy and pancreatoscopy use has become ubiquitous with defined indications for large bile duct stones,indeterminate strictures,and hepatobiliary and pancreatic neoplasia.This review summarizes the recent advances in infection prevention,quality improvement,pancreaticobiliary access,and management of hepatobiliary and pancreatic diseases.Where appropriate,future research directions are included in each section. | David J Sanders Shivanand Bomman Rajesh Krishnamoorthi Richard A Kozarek | 2021 | World Journal of Gastrointestinal Endoscopy2021，13，8： | 5 |
| 6 | ATG16L1 and NOD2 polymorphisms enhance phagocytosis in monocytes of Crohn's disease patients显示文摘AIM:To investigate if the presence of relevant genetic polymorphisms has effect on the effectual clearance of bacteria by monocytes and granulocytes in patients with Crohn’s disease(CD).METHODS:In this study,we assessed the differential responses in phagocytosis by measuring the phagocytic activity and the percentage of active phagocytic monocytes and granulocytes in inflammatory bowel disease patients as well as healthy controls.As both autophagy related like 1(ATG16L1)and immunityrelated guanosine triphosphatase gene are autophagy genes associated with CD and more recently nucleo-tide-binding ligomerization domain-containing protein2(NOD2)has been identified as a potent inducer of autophagy we genotyped the patients for these variants and correlated this to the phagocytic reaction.The genotyping was done with restriction fragment length polymorphisms analysis and the phagocytosis was determined with the pHrodo?Escherichia coli Bioparticles Phagocytosis kit for flowcytometry.RESULTS:In this study,we demonstrate that analysis of the monocyte and granulocyte populations of patients with CD and ulcerative colitis showed a comparable phagocytic activity(ratio of mean fluorescence intensity)between the patient groups and the healthy controls.CD patients show a significantly higher phagocytic capacity(ratio mean percentage of phagocytic cells)compared to healthy controls(51.91%±2.85%vs 37.67%±7.06%,P=0.05).The extend of disease was not of influence.However,variants of ATG16L1(WT:2.03±0.19 vs homozygoot variant:4.38±0.37,P<0.009)as well as NOD2(C-ins)(heterozygous variant:42.08±2.94 vs homozygous variant:75.58±4.34(P=0.05)are associated with the phagocytic activity in patients with CD.CONCLUSION:Monocytes of CD patients show enhanced phagocytosis associated with the presence of ATG16L1 and NOD2 variants.This could be part of the pathophysiological mechanism resulting in the disease. | Simone CS Wolfkamp Caroline Verseyden Esther WM Vogels Sander Meisner Kirsten Boonstra Charlotte P Peters Pieter CF Stokkers Anje A te Velde | 2014 | World Journal of Gastroenterology2014，20，10： | 2 |
| 7 | Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies显示文摘 | Lehmann Brian D Bauer Joshua A Chen Xi Sanders Melinda E Chakravarthy A Bapsi Shyr Yu Pietenpol Jennifer A | 2011 | Journal of Clinical Investigation2011，，7： | 2 |
| 8 | Elastic and tensile behavior of nanocrystalline copper and palladium显示文摘 | Sanders P G Eastman J A Weertman J R | 1997 | Acta Mater1997，45，10： | 2 |
| 9 | Immunity:研究开发出最优的HIV疫苗递送模式显示文摘HIV已不再占据头条新闻。这主要是因为抗逆转录病毒药物的成功开发已将HIV病毒感染导致的艾滋病(AIDS)转化为一种慢性的可控制的疾病。然而。当前在全世界大约0.367亿名HIV感染者中,仅约一半的人能够获得控制这种病毒所需的药物。与此同时。新的HIV感染率持续保持在非常高的水平,这突出强调了需要开发一种预防性疫苗。然而,几十年来。 | Matthias Pauthner Colin Havenar-Daughton Devin Sok Joseph P. Nkolola Raiza Bastidas Archana V. Boopathy Diane G. Carnathan Abishek Chandrashekar Kimberly M. Cirelli Christopher A. Cottrell Alexey M. Eroshkin Javier Guenaga Kirti Kaushik Daniel W. Kulp Jinyan Liu Laura E. McCoy Aaron L. Oom Gabriel Ozorowski Kai W. Post Shailendra K. Sharma Jon M. Steichen Steven W. de Taeye Talar Tokatlian Alba Torrents de la Peña Salvatore T. Butera Celia C. LaBranche David C. Montefiori Guido Silvestri Ian A. Wilson Darrell J. Irvine Rogier W. Sanders William R. Schief Andrew B. Ward Richard T. Wyatt Dan H. Barouch Shane Crotty Dennis R. Burton | 2017 | 现代生物医学进展2017，17，27： | 2 |
| 10 | Architecture and IC implementation of a digital VRM controller显示文摘 | Peterchev A V Xiao Jinwen Sanders S R | 2003 | IEEE Transactions on Power Electronics2003，18，1： | 1 |
| 11 | CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo 显示文摘 | Lapteva N Yang A G Sanders D E | 2005 | Cancer Gene Ther2005，12，1： | 1 |
| 12 | Acrylamide formation mechanism in heated foods 显示文摘 | Zyzak D V Sanders R A Stojanovic M | 2003 | Journal of Agricultural and Food Chemistry2003，51，16： | 1 |
| 13 | Response of bacterioplankton and phytoplankton to organic carbon and inorganic nutrient additions in contrasting oceanic ecosystems显示文摘 | Caron D A Lira E L Sanders R W | 2000 | Aquatic Microbial Ecology2000，22，： | 1 |
| 14 | Complete genomes of two clinical Staphylococcus aureus strains:evidence for the rapid evolution of virulence and drug resistance显示文摘 | Holden MT Feil EJ Lindsay JA Peacock SJ Day NP Enright MC Foster TJ Moore CE Hurst L Atkin R Barron A Bason N Bentley SD Chillingworth C Chillingworth T Churcher C Clark L Corton C Cronin A Doggett J Dowd L Feltwell T Hance Z Harris B Hauser H Holroyd S Jagels K James KD Lennard N Line A Mayes R Moule S Mungall K Ormond D Quail MA Rabbinowitsch E Rutherford K Sanders M Sharp S Simmonds M Stevens K Whitehead S Barrell BG Spratt BG Parkhill J | 2004 | Proc Natl Acad Sci USA2004，101，26： | 1 |
| 15 | Different arbuscular mycorrhizal fungi species are potential determinants of plant community structure显示文摘 | Van der Heijden MGA Boller T Wiemken A Sanders IR | 1998 | Ecology1998，79，： | 1 |
| 16 | Expired PCOz as an index of coronary perfusion pressure显示文摘 | SANDERS A B ATLAS M EWY G A | 1985 | Am J Emerg Med1985，3，2： | 1 |
| 17 | Determination of organic acids in Vaccinium berry standard reference materials显示文摘 | Phillips M M Case R J Rimmer C A Sander L C Sharpless K E Wise S A Yen J H | 2010 | Analytical and Bioanalytical Chemistry2010，398，1： | 1 |
| 18 | Plasticiser effect of oleic acid polyester on polyethylene and polypropyl- ene 显示文摘 | SANDER M M NICOLAU A GUZATTO R | 2012 | PolymTest2012，，8： | 1 |
| 19 | Guidelines on smallbowel enterosco- py and capsule endoscopy in adults显示文摘 | Sidhu R Sanders D S Morris A J | 2008 | Gut2008，57，1： | 1 |
| 20 | Open reduction and internal fixation ofdelayed union and nonunion of the distal humerus显示文摘 | Sanders R A Sackett J R | 1990 | J Orthop Traum1990，4，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员